In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists.
暂无分享,去创建一个
B. Drolet | J. Turgeon | A. Bouayad | B A Hamelin | A Bouayad | B Drolet | A Gravel | J Turgeon | A. Gravel | B. Hamelin
[1] T. Kamataki,et al. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. , 1996, Pharmacogenetics.
[2] S. Imaoka,et al. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. , 1995, The Journal of pharmacology and experimental therapeutics.
[3] N. Vermeulen,et al. A refined substrate model for human cytochrome P450 2D6. , 1997, Chemical research in toxicology.
[4] S. Symchowicz,et al. Metabolism of chlorpheniramine maleate in man. , 1972, The Journal of pharmacology and experimental therapeutics.
[5] S F Pong,et al. Comparative studies on distribution, excretion, and metabolism of hydroxyzine-3H and its methiodide-14C in rats. , 1974, Journal of pharmaceutical sciences.
[6] J. Houston,et al. Simultaneous determination of promethazine and two of its circulating metabolites by high-performance liquid chromatography. , 1982, Journal of chromatography.
[7] W. L. Chiou,et al. Long half-life of chlorpheniramine. , 1979, The New England journal of medicine.
[8] T. Kronbach,et al. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. , 1987, Analytical biochemistry.
[9] M. Ghoneim,et al. Diphenhydramine in Orientals and Caucasians , 1980, Clinical pharmacology and therapeutics.
[10] M. Lennard. Genetically Determined Adverse Drug Reactions Involving Metabolism , 1993, Drug safety.
[11] C. Gorodetzky,et al. The pharmacokinetics of pentazocine and tripelennamine , 1986, Clinical pharmacology and therapeutics.
[12] J. Idle,et al. POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.
[13] F. Simons,et al. The pharmacology and use of H1-receptor-antagonist drugs. , 1994, The New England journal of medicine.
[14] W. L. Chiou,et al. Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults , 2004, European Journal of Clinical Pharmacology.
[15] D. Greenblatt,et al. Pharmacokinetics of Diphenhydramine and a Demethylated Metabolite Following Intravenous And Oral Administration , 1986, Journal of clinical pharmacology.
[16] C. Hignite,et al. Correlation between plasma diphenhydramine level and sedative and antihistamine effects. , 1979, Clinical pharmacology and therapeutics.
[17] K. Simons,et al. The pharmacokinetics and antihistaminic effects of brompheniramine. , 1982, The Journal of allergy and clinical immunology.
[18] C. Hignite,et al. Correlation between plasma diphenhydramine level and sedative and antihistamine effects , 1978 .
[19] A. Wellstein,et al. Chlorpheniramine plasma concentration and histamine H1‐receptor occupancy , 1995, Clinical pharmacology and therapeutics.
[20] G. Krishna,et al. Metabolism, tissue distribution and covalent binding of tripelennamine and its N-nitroso derivative in the rat. , 1975, The Journal of pharmacology and experimental therapeutics.
[21] J. Yeh,et al. Distribution, excretion, and metabolism of 14C-labeled quaternary ammonium salt of mepazine and promethazine in rats. , 1970, Journal of pharmaceutical sciences.
[22] K. Simons,et al. The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. , 1984, The Journal of allergy and clinical immunology.
[23] L. Bertilsson,et al. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. , 1987, Pharmacology & toxicology.
[24] U. Meyer,et al. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. , 1988, Biochemical pharmacology.
[25] D. Miller,et al. Metabolism of chlorpheniramine-3H by the rat and dog. , 1969, Biochemical pharmacology.
[26] G. Jones,et al. Site dependence of drug concentrations in postmortem blood--a case study. , 1987, Journal of analytical toxicology.
[27] G. Alván,et al. Clinical consequences of polymorphic drug oxidation , 1991, Fundamental & clinical pharmacology.
[28] R. Nation,et al. Chlorpheniramine. I. Rapid quantitative analysis of chlorpheniramine in plasma, saliva and urine by high-performance liquid chromatography. , 1979, Journal of chromatography.
[29] M. Ghoneim,et al. Diphenhydramine: Kinetics and psychomotor effects in elderly women , 1982, Clinical pharmacology and therapeutics.
[30] M. Tsuang,et al. Idiosyncratic pharmacokinetics complicating treatment of major depression in an elderly woman. , 1985, The Journal of nervous and mental disease.
[31] A. Bacigalupo,et al. Bolus methylprednisolone in severe aplastic anemia. , 1979, The New England journal of medicine.
[32] D. Paton,et al. Clinical Pharmacokinetics of H1-Receptor Antagonists (The Antihistamines) , 1985, Clinical pharmacokinetics.